Henry Purbrick is a final-year CSIRO Industry PhD candidate at the University of Western Australia and Harry Perkins Institute of Medical Research, undertaking his research in collaboration with Dimerix, a Melbourne-based biopharmaceutical company. Using live-cell biosensors, amongst other in vitro methodologies, his project aims to discover unique signalling mechanisms of novel GCPR heteromers as potential therapeutic targets for complex inflammatory diseases. Beyond his laboratory research, Henry completed an internship with Dimerix, where he explored translational strategies for potential pipeline candidates. Actively involved in committees, Henry is the current Chair of the Perkins Student Committee, and student representative of the ASCEPT Industry & Innovation special interest group.

Zhaoyi Yang, MD, is an Associate Chief Pharmacist and Master Supervisor with extensive experience in clinical pharmacology. As a Principal Investigator, Dr. Yang has led over 20 Phase I clinical trials, contributing significantly to the advancement of early-stage drug development. In addition to clinical work, Dr. Yang holds multiple academic and professional positions. He is a member of the Clinical Pharmacology Committee of the Chinese Pharmacological Society and a young member of the Drug Clinical Trials Committee of the same society. At the regional level, he serves as Vice Chairman of the Anti-inflammatory and Immune Pharmacology Committee and as a member and Deputy Secretary-General of the Clinical Pharmacology Committee of the Anhui Pharmacological Society. He is also a standing member of the Drug Clinical Evaluation Committee and part of the Drug Clinical Research and Evaluation Special Committee of the Anhui Medical Doctor Association. Dr. Yang’s work bridges clinical research, pharmacology, and academic leadership, advancing safe and effective therapeutics in China.